Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress
4
조회
0
다운로드
0
인용
0
참고문헌
초록
Src family kinases (SFKs) have been implicated in the pathogenesis of kidney fibrosis. However, the specific mechanism by which SFKs contribute to the progression of diabetic kidney disease (DKD) remains unclear. Our preliminary transcriptome analysis suggested that SFK expression was increased in diabetic kidneys and that the expression of Fyn (a member of the SFKs), along with genes related to unfolded protein responses from the endoplasmic reticulum (ER) stress signaling pathway, was upregulated in the tubules of human diabetic kidneys. Thus, we examined whether SFK-induced ER stress is associated with DKD progression. Mouse proximal tubular (mProx24) cells were transfected with Fyn or Lyn siRNA and exposed to high glucose and palmitate (HG-Pal). Streptozotocin-induced diabetic rats were treated with KF-1607, a novel pan-Src kinase inhibitor (SKI) with low toxicity. The effect of KF-1607 was compared to that of losartan, a standard treatment for patients with DKD. Among the SFK family members, the Fyn and Lyn kinases were upregulated under diabetic stress. HG-Pal induced p70S6 kinase and JNK/CHOP signaling and promoted tubular injury. Fyn knockdown but not Lyn knockdown inhibited this detrimental signaling pathway. In addition, diabetic rats treated with KF-1607 showed improved kidney function and decreased ER stress, inflammation, and fibrosis compared with those treated with losartan. Collectively, these findings indicate that Fyn kinase is a specific member of the SFKs implicated in ER stress activation leading to proximal tubular injury in the diabetic milieu and that pan-SKI treatment attenuates kidney injury in diabetic rats. These data highlight Fyn kinase as a viable target for the development of therapeutic agents for DKD.
Abstract
Src family kinases (SFKs) have been implicated in the pathogenesis of kidney fibrosis. However, the specific mechanism by which SFKs contribute to the progression of diabetic kidney disease (DKD) remains unclear. Our preliminary transcriptome analysis suggested that SFK expression was increased in diabetic kidneys and that the expression of Fyn (a member of the SFKs), along with genes related to unfolded protein responses from the endoplasmic reticulum (ER) stress signaling pathway, was upregulated in the tubules of human diabetic kidneys. Thus, we examined whether SFK-induced ER stress is associated with DKD progression. Mouse proximal tubular (mProx24) cells were transfected with Fyn or Lyn siRNA and exposed to high glucose and palmitate (HG-Pal). Streptozotocin-induced diabetic rats were treated with KF-1607, a novel pan-Src kinase inhibitor (SKI) with low toxicity. The effect of KF-1607 was compared to that of losartan, a standard treatment for patients with DKD. Among the SFK family members, the Fyn and Lyn kinases were upregulated under diabetic stress. HG-Pal induced p70S6 kinase and JNK/CHOP signaling and promoted tubular injury. Fyn knockdown but not Lyn knockdown inhibited this detrimental signaling pathway. In addition, diabetic rats treated with KF-1607 showed improved kidney function and decreased ER stress, inflammation, and fibrosis compared with those treated with losartan. Collectively, these findings indicate that Fyn kinase is a specific member of the SFKs implicated in ER stress activation leading to proximal tubular injury in the diabetic milieu and that pan-SKI treatment attenuates kidney injury in diabetic rats. These data highlight Fyn kinase as a viable target for the development of therapeutic agents for DKD.
참고문헌 (48)
- Webster, A. C., "Chronic kidney disease", Lancet, 389, pp.1238~1252 (2017)
- Thomas, M. C., "Diabetic kidney disease", Nat. Rev. Dis. Prim, 1, pp.1~19 (2015)
- Tomotaka Yamazaki, "Treatment of Diabetic Kidney Disease: Current and Future", Diabetes and Metabolism Journal, 45(1), pp.11~26 (2021), 대한당뇨병학회[DOI]
- Boggon, T. J., "Structure and regulation of Src family kinases", Oncogene, 23, pp.7918~7927 (2004)
- Choudhury, G. G., "c-Src couples PI 3 kinase", Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells, 2006, pp.18, 1854~1864
- Taniguchi, K., "Inhibition of src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice", Diabetes, 62, pp.3874~3886 (2013)
- Yan, Y., "Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis", Kidney Int, 89, pp.68~81 (2016)
- Seo, H. Y., "Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3", Kidney Int, 90, pp.1285~1297 (2016)
- Wei, C., "Genomic analysis of kidney allograft injury identifies hematopoietic cell kinase as a key driver of renal fibrosis", J. Am. Soc. Nephrol, 28, pp.1385~1393 (2017)
- Dorotea Debra, "KF-1607, a Novel Pan Src Kinase Inhibitor, Attenuates Obstruction-Induced Tubulointerstitial Fibrosis in Mice", Biomolecules & Therapeutics, 29(1), pp.41~51 (2021), 한국응용약물학회[DOI]
- Liu, F., "Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease", Clin. Sci, 131, pp.2125~2143 (2017)
- Wu, H., "Inhibition of c-Src", p38 MAPK pathway ameliorates renal tubular epithelial cells apoptosis in db, Mol. Cell. Endocrinol, pp.2015, 417[DOI]
- Wang, Y., "Fyn activation of mTORC1 stimulates the IRE1 α-JNK pathway, leading to cell death", J. Biol. Chem, 290, pp.24772~24783 (2015)
- Lee, J. Y., "Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate.", Am. J. Physiol. Ren. Physiol, 300, pp.1214~1222 (2011)
- Tang, X., "ATF6 pathway of unfolded protein response mediates advanced oxidation protein product-induced hypertrophy and epithelial-to-mesenchymal transition in HK-2 cells", Mol. Cell. Biochem, 407, pp.197~207 (2015)
- Cunard, R., "The endoplasmic reticulum stress response and diabetic kidney disease", Am. J. Physiol. Ren. Physiol, 300, pp.1054~1061 (2011)
- Qiu, C., "Renal compartment–specific genetic variation analyses identify new pathways in chronic kidney disease", Nat. Med, 24, pp.1721~1731 (2018)
- Fan, Y., "The role of endoplasmic reticulum stress in diabetic nephropathy", Curr. Diab. Rep, 17, pp.17~ (2017)
- Dorotea, D., "A pan-NADPH oxidase inhibitor ameliorates kidney injury in type 1 diabetic rats", Pharmacology, 102, pp.180~189 (2018)
- Ha, H., "Melatonin and taurine reduce early glomerulopathy in diabetic rats", Free Radic. Biol. Med, 26, pp.944~950 (1999)
- Papadopoulos, T., "Omics databases on kidney disease : Where they can be found and how to benefit from them", Clin. Kidney J, 9, pp.343~352 (2016)
- Woroniecka, K. I., "Transcriptome analysis of human diabetic kidney disease", Diabetes, 60, pp.2354~2369 (2011)
- Nakagawa, S., "Molecular markers of tubulointerstitial fibrosis and tubular cell damage in patients with chronic kidney disease", PLoS ONE, 10, pp.1~14 (2015)
- Hodgin, J. B., "Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli", Diabetes, 62, pp.299~308 (2013)
- Croft, D., "Reactome : a database of reactions, pathways and biological processes", Nucleic Acids Res, 39, pp.D691~D697 (2011)
- Yasuda, M., "Fatty acids are novel nutrient factors to regulate mTORC1lysosomal localization and apoptosis in podocytes", Biochim. Biophys. Acta Mol. Basis Dis, 1842, pp.1097~1108 (2014)
- Kuwagata, S., "MicroRNA148b-3p inhibits mTORC1-dependent apoptosis in diabetes by repressing TNFR2 in proximal tubular cells", Kidney Int, 90, pp.1211~1225 (2016)
- Pal, R., "Src regulates amino acid-mediated mTORC1 activation by disrupting GATOR1-Rag GTPase interaction", Nat. Commun, 9, pp.4351~ (2018)
- Muskiet, M. H. A., "The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?", Nat. Rev. Nephrol, 10, pp.88~103 (2014)
- Liu, Y., "New insights into epithelial-mesenchymal transition in kidney fibrosis", J. Am. Soc. Nephrol, 21, pp.212~222 (2010)
- Lee, T. W. A., "Fyn deficiency promotes a preferential increase in subcutaneous adipose tissue mass and decreased visceral adipose tissue inflammation", Diabetes, 62, pp.1537~1546 (2013)
- Bastie, C. C., "Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the Src kinase family member Fyn", Cell Metab, 5, pp.371~381 (2007)
- Kato, H., "MTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway", Cell Death Differ, 19, pp.310~320 (2012)
- Yamada, E., "Mouse skeletal muscle fiber-type-specific macroautophagy and muscle wasting are regulated by a Fyn", STAT3, Cell Rep, pp.2012, 1[DOI]
- Yamada, E., "Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1", Cell Metab, 11, pp.113~124 (2010)
- Ruderman, N. B., "AMPK, insulin resistance, and the metabolic syndrome", J. Clin. Invest, 123, pp.2764~2772 (2013)
- Steinberg, G. R., "AMP-activated protein kinase: the current landscape for drug development", Nat. Rev. Drug Discov, 18, pp.527~551 (2019)
- Hwang, S. L., "AMP-activated protein kinase negatively regulates FcεRImediated mast cell signaling and anaphylaxis in mice", J. Allergy Clin. Immunol, 132, pp.729~736 (2013)
- Mkaddem, S. B., "Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation", Nat. Commun, 8, pp.246~ (2017)
- Mima, A., "Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy", Lab. Investig, 86, pp.927~939 (2006)
- Komers, R., "Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment", PLoS ONE, 9, pp.e96987~ (2014)
- Yang, J., "Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation", Int. J. Mol. Med, 39, pp.613~621 (2017)
- Kawai, T., "AT1 receptor signaling pathways in the cardiovascular system", Pharmacol. Res, 125, pp.4~13 (2017)
- Whaley-Connell, A., "Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin", Am. J. Nephrol, 34, pp.115~125 (2011)
- Kim, S. -M., "Csk regulates blood pressure by controlling the synthetic pathways of aldosterone", Circ. J, 82, pp.168~175 (2018)
- Sovari, A. A., "Inhibition of c-Src tyrosine kinase prevents angiotensin IImediated connexin-43 remodeling and sudden cardiac death", J. Am. Coll. Cardiol, 58, pp.2332~2339 (2011)
- Beyer, C., "Tyrosine kinase signaling in fibrotic disorders. Translation of basic research to human disease", Biochim. Biophys. Acta Mol. Basis Dis, 1832, pp.897~904 (2013)
- Van Dyck, C. H., "Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease : a randomized clinical trial", JAMA Neurol, 76, pp.1219~1229 (2019)